




1 QuikClot Control +TM

For Use in
General Surgery





QuikClot Control+® Hemostatic Device

- QuikClot Control+™ is intended to be used on all patient populations where control of bleeding is required due to injuries and/or surgical wounds
- Suitable for both internal and external use
- May be left in place for up to 48 hours



Same Technique

- Same technique as standard gauze or laparotomy pads with more bleeding control in less time^{1,2}



Stronger Clot

- Robust clot forms quickly to deliver better bleeding control than standard gauze^{3,4}



Faster Bleeding Control


- Faster hemostasis may improve visualisation of the surgical field⁵
- Improved visualisation may allow for quicker identification of definitive repair needs

Mode of action

Apply to bleeding source

Accelerate the body's normal clotting cascade

Achieve fast bleeding control




Safety and efficacy of a kaolin-impregnated hemostatic gauze in cardiac surgery: A randomized trial

Mubashir Mumtaz, MD,^a Richard B. Thompson, MD,^b Marc R. Moon, MD,^c Ibrahim Sultan, MD,^d T. Brett Reece, MD,^e William B. Keeling, MD,^f and Jacob DeLaRosa, MD^g

CENTRAL MESSAGE

QuikClot Control+ was superior to standard gauze in achieving hemostasis for mild (grade 1)/moderate (grade 2) cardiac surgery bleeding, with QuikClot Control+ subjects achieving hemostasis at more than 20% higher proportion at 5 and 10 minutes versus controls.



Subject proportions achieved hemostasis at 5 and 10 minutes: QCC+ (blue) and control (navy)

■ QuikClot Control+
■ Control

Safety and Efficacy of a Kaolin-Impregnated Hemostatic Gauze in Cardiac Surgery: a Randomized Trial

- 231 cardiac surgery patients
- Age > 18 years
- Mid to moderate bleeding
- Jun. 2020 – Sep. 2021
- 7 Study Sites

Randomization



QCC+ (n=153)
Kaolin-impregnated hemostatic Gauze

Standard Gauze (control; n=78)

Cardiac surgery
• CABG
• Valve repair/replacement
• Aortic aneurysm repair

No significant differences in safety or adverse events between treatment arms



Hemostasis achieved in 20.7% (5 mins) and 21.4% (10 mins) more QCC+ subjects compared to controls (P < .001)

Primary efficacy endpoint: hemostasis rate (i.e. Grade 0 bleed) through up to 10 mins of bleeding site application

Interval censored time-to-hemostasis assessments at 5 and 10 mins.

Variable	QCC+ (n = 153)	Standard Gauze (n = 78)	P-Value
Hemostasis rate at 5 mins.	121/153 (79.1%)	45/78 (58.4%)	<.001
Hemostasis rate at 10 mins.	137/153 (89.8%)	52/78 (68.4%)	<.001

Implications: QCC+ hemostatic gauze may be preferable to standard gauze for achieving hemostasis in mild to moderate cardiac surgery bleeding

QCC+ QuickClot Control +™, CABG: Coronary Artery Bypass Graft

Indications

QuikClot Control+ is indicated for temporary control of internal and external mild, moderate, severe, and traumatic bleeding due to injuries and/or surgical wounds.

Intended Purpose:

QuikClot Control+ is intended for control of internal and external bleeding.

Contraindications:

QuikClot Control+ is not indicated for intraluminal vascular use.

Intended Users:

Clinicians trained in the management of internal and external bleeding.

Patient Target Group:

QuikClot Control+ is intended to be used on all patient populations where control of bleeding is required due to injuries and/or surgical wounds.

Clinical Benefit:

The patient may expect the benefit of bleeding control at the site of application.

QuikClot™ Control+™ Product Offering

REF.	PRODUCT	DESCRIPTION	BOX QTY
4100	QuikClot™ Control +™ 5X5	12cmx12cm in 4 ply	10
4110	QuikClot™ Control +™ 8x8	20cmx20cm in 2 ply	10
4120	QuikClot™ Control +™ Z-Fold	7.6cm x 1.8m in 1 ply	10
4130	QuikClot™ Control +™ 12x12	30cmx30cm in 3 ply	10

References

1. Data on file at Teleflex. As compared to laparotomy pads.
2. Kheirabadi BS, Mace JE, Terrazas IB, et al. J Trauma. 2010;68(2):269-278. Pre-clinical study.
3. Garcia-Blanco J, Gegel B, Burgert J, et al. J Spec Oper Med. 2015;15(1):57-60.
4. Johnson D, Westbrook DM, Phelps D, et al. Am J Disaster Med. 2014;9(4):309-315.
5. Moss R. 2013; 1-39. <https://www.aorn.org/-/media/aorn/guidelines/tool-kits/medication-safety/management-of-surgical-hemostasisindependent-study-guide.pdf?la=en&hash=9FED3DF8BFDEF8B1C8D1899F8FC7BE79>. Accessed September 6, 2022

Teleflex, the Teleflex logo, QuikClot and QuikClot Control + are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries. Please contact your local representative. Revised: 08/2024.

© 2024 Teleflex Incorporated. All rights reserved. MCI-101805 · REV 0 · 08 24 PDF

Distributed by:

Teleflex Headquarters International, Ireland · Teleflex Medical Europe Ltd. · IDA Business & Technology Park
Dublin Road · Athlone · Co Westmeath · Tel. +353 (0)9 06 46 08 00 · Fax +353 (0)14 37 07 73 · orders.intl@teleflex.com
United Kingdom Tel. +44 (0)14 94 53 27 61 · info.uk@teleflex.com
South Africa Tel. +27 (0)11 807 4887 · assist.africa@teleflex.com

[teleflex.com/...](https://teleflex.com/)

Teleflex™
Empowering the future of healthcare